Eli Lillys Mounjaro shows similar heart performance for heart as trulicity

Mounjaro, which was made by Eli Lilly and Company Packaging, can be seen in this illustration photo in a pharmacy in Krakow, Poland, on April 9, 2024.

Nurphoto | Nurphoto | Getty pictures

Eli Lilly On Thursday, his blockbuster-diabetes medication-mounjaro showed in a study in the late stage, in which he led directly with the company's older diabetes treatment, the company's trulicity.

Mounjaro met the main goal of the study to show that it was no worse than treating people with type -2 diabetes and cardiovascular diseases. Eli Lilly believes that the new data is that Mounjaro is the first choice for patients with type -2 diabetes who have a heart disease or a heart disease or stroke twice as likely with heart disease or a stroke.

The results come as a trulicity, if necessary, a best-selling medication for Eli Lilly-in front of a patent in 2027, which could further increase Mounjaro's position on the diabetes market.

Mounjaro reached the main goal of the almost five-year study and reduced the risk of cardiovascular death, heart attack or stroke by 8% compared to trulicity in adults with type 2 diabetes and cardiovascular diseases. However, the results did not meet the benchmarks of some analysts because they were considered superior to trulicity.

Nevertheless, the company said that Mounjaro showed additional, “more comprehensive” advantages over the trulicity in the study, including a lower death rate of 16% of any cause and greater kidney protection. It was the longest and greatest attempt with Tirzatide, the active ingredient in Mounjaro, which included more than 13,000 people.

Some clinicians said that the results, in particular the reduced risk of cardiovascular events, are not surprising because they assumed that Mounjaro could offer cardiovascular advantages.

But the difference in the death rate for some reason between Mounjaro and Trulicity is “really very profound” and “definitely a little clinical as a clinician,” said Dr. David Broome, clinical assistant professor at the Department of Internal Medical Code, Endocrinology and Diabetes Department at the University of Michigan.

He said the data had contributed to quantifying the difference between Mounjaro and Trulicity, which will help the providers and patients to determine the best treatment in order to advance them in their joint decisions. Broome said that the prescription decisions between patients and providers will ultimately depend on several factors, such as:

Dr. Howard Weintraub, clinical director of the center to prevent cardiovascular diseases at Nyu Langone Heart, described Mounjaro as a “winner” in the study, with the only disadvantage of him having a little more side effects than trulicity. But he said that the results may no longer motivate people to found Mounjaro, and that the higher list price of the drug could prevent insurers from covering it if it is not much better than the trulicity.

Wine grayer said he expects a lot of “dig” when the complete results were presented at a European medical meeting and published in autumn in a diary assessed by experts.

Eli Lilly saw the study results as an indicator that clinicians should choose Mounjaro for the patient group.

“It strengthens the overall story. In my opinion, the question raises:” Why wouldn't you choose Mounjaro? “,” Said Ken Custer, President of the Lilly Cardiometabolic Health.

The results “take doubts about why this is the right medication for a patient with type -2 -diabetes and type -2 -2 diabetes with cardiovascular risk,” he said, adding that it “makes it even more difficult to cover this drug for patients”.

The results also come when Eli Lilly solidified his lead Novo Nordisk On the booming market for weight loss and diabetes medication. Studies of both companies have shown the additional health benefits of their medicines for diseases such as obstructive sleep apnea and chronic kidney diseases.

Eli Lilly plans to submit the heart health data to the global supervisory authorities by the end of the year, and the company said this could lead to permits – and as part of the insurance company – by Mounjaro for this purpose in 2026. All approvals do not apply to Eli Lilly's weight loss drug -zepbound, the same active ingredient as Mooonjar, which deals with patients with darkness and not with insulation and non -denting.

The company is currently investigating the cardiovascular advantages of Zepbound in patients with obesity and specified cardiovascular diseases. According to Eli Lilly's website, the attempt by phase three is expected to be completed in 2027.

Even if the regulatory authorities agree with Mounjaro for the treatment of heart diseases in patients with type -2 -diabetes, this may not significantly expand the use of the drug. This is because the current admission of Mounjaro for Type -2 -Diabetes already covers many of these patients: According to the Heart Foundation, around 30% of people with type -2 diabetes also have a cardiovascular disease.

In a research note in June before the data, the TD Cowen -Analyst Steve Scala said that he believed that the inclusion of Tireptide would “be largely untouched” if this has similar health from the heart of trulicity.

Tirepatide “already gains” considerable acceptance “on the market due to its” strong profile “, said the analyst of Leerink Partners, David Risinger, in a separate hint in June. He said that the experts agreed that the results” would not change the decisions of doctors “regardless of whether the cardiovascular advantages of Tirzepatide were superior in the study Study.

Mounjaro showed a greater improvements than the trulicity than it was about some cardiovascular measures and the reduction in body weight and A1C, which is a measure of blood sugar levels.

The safety data of Mounjaro and Trulicity generally agreed with the past that was observed in the past. The most frequently reported unwanted events for both medicines were gastrointestinal and generally slightly to moderate heaviness.

– Angelica Peebles from CNBC contributed to this report.